Molecular structure of Cobicistat, CAS Number: 1004316-88-4
Cobicistat (CAS 1004316-88-4)
See product citations (2)
CAS Number:
1004316-88-4
Molecular Weight:
776.02
Molecular Formula:
C40H53N7O5S2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Cobicistat is a powerful, selective, and reversible inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme, cobicistat has been noted for its capacity to enhance the bioavailability of certain compounds. The substance operates by suppressing the CYP3A4 enzyme′s function, which is known for its role in the metabolism of a wide array of substances. Through this inhibition, cobicistat has the potential to maintain higher levels of specific compounds in the system. Its role in research focuses on understanding its impact on the metabolism and bioavailability of other compounds, with a particular focus on how it affects their presence and longevity within the system.
Cobicistat (CAS 1004316-88-4) References
- Cobicistat: a new boost for the treatment of human immunodeficiency virus infection. | Shah, BM., et al. 2013. Pharmacotherapy. 33: 1107-16. PMID: 23471741
- Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection. | Deeks, ED. 2014. Drugs. 74: 195-206. PMID: 24343782
- Darunavir/cobicistat once daily for the treatment of HIV. | Kakuda, TN., et al. 2015. Expert Rev Anti Infect Ther. 13: 691-704. PMID: 25962100
- Cobicistat: Review of a Pharmacokinetic Enhancer for HIV Infection. | Sherman, EM., et al. 2015. Clin Ther. 37: 1876-93. PMID: 26319088
- Darunavir/cobicistat for the treatment of HIV-1: a new era for compact drugs with high genetic barrier to resistance. | Capetti, A., et al. 2015. Expert Opin Pharmacother. 16: 2689-702. PMID: 26612518
- Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for the treatment of HIV in adults. | Bonora, S., et al. 2016. Expert Opin Pharmacother. 17: 409-19. PMID: 26642079
- Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection. | Greig, SL. and Deeks, ED. 2016. Drugs. 76: 957-68. PMID: 27189707
- Drug Interactions with Cobicistat- or Ritonavir-Boosted Elvitegravir. | Nguyen, T., et al. 2016. AIDS Rev. 18: 101-11. PMID: 27196356
- [Pharmacological aspects of darunavir/cobicistat]. | González-Domenech, CM., et al. 2016. Enferm Infecc Microbiol Clin. 34 Suppl 1: 30-33. PMID: 28081761
- Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection. | Deeks, ED. 2018. Drugs. 78: 1013-1024. PMID: 29915897
- Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era. | Squillace, N., et al. 2018. Drug Des Devel Ther. 12: 3635-3643. PMID: 30464395
- Pharmacokinetic drug evaluation of ritonavir (versus cobicistat) as adjunctive therapy in the treatment of HIV. | Cattaneo, D., et al. 2019. Expert Opin Drug Metab Toxicol. 15: 927-935. PMID: 31668105
Inhibitor of:
CYP3A5, HHV-8 B, HIV-1 Protease, and OATP-I.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Cobicistat, 5 mg | sc-500831 | 5 mg | $350.00 |